Sun Pharmaceutical Industries says it will acquire 100% of Invocare Lifesciences for Rs 271 crore. According to the report, the company is described as framing the deal as a strategic investment aimed at strengthening its product portfolio. The sources provided do not include additional details such as the transaction timeline, regulatory approvals required, or how the acquired business will be integrated into Sun Pharma’s existing operations. No information is given on whether the acquisition affects specific products, customer segments, or manufacturing assets. The reports also do not specify whether the purchase is structured as a share purchase alone or includes any other components. Overall, the available coverage is focused on the deal size and the stated rationale from Sun Pharma—expanding and reinforcing its portfolio—while leaving out further commercial and operational specifics.